MX2019014318A - Proteinas de union a nectina-4 y metodos de uso de las mismas. - Google Patents
Proteinas de union a nectina-4 y metodos de uso de las mismas.Info
- Publication number
- MX2019014318A MX2019014318A MX2019014318A MX2019014318A MX2019014318A MX 2019014318 A MX2019014318 A MX 2019014318A MX 2019014318 A MX2019014318 A MX 2019014318A MX 2019014318 A MX2019014318 A MX 2019014318A MX 2019014318 A MX2019014318 A MX 2019014318A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nectin
- binding proteins
- assessing
- cancer
- Prior art date
Links
- 102100035486 Nectin-4 Human genes 0.000 title abstract 3
- 101710043865 Nectin-4 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515454P | 2017-06-05 | 2017-06-05 | |
| PCT/US2018/035840 WO2018226578A1 (en) | 2017-06-05 | 2018-06-04 | Nectin-4-binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014318A true MX2019014318A (es) | 2020-08-13 |
Family
ID=64566092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014318A MX2019014318A (es) | 2017-06-05 | 2018-06-04 | Proteinas de union a nectina-4 y metodos de uso de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11292837B2 (OSRAM) |
| EP (1) | EP3635013A4 (OSRAM) |
| JP (1) | JP7168590B2 (OSRAM) |
| KR (1) | KR102723905B1 (OSRAM) |
| CN (2) | CN111675761B (OSRAM) |
| BR (1) | BR112019025513A2 (OSRAM) |
| CA (1) | CA3065514A1 (OSRAM) |
| MX (1) | MX2019014318A (OSRAM) |
| TW (1) | TWI870338B (OSRAM) |
| WO (1) | WO2018226578A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| EP3890778A4 (en) | 2018-12-03 | 2022-08-03 | Agensys, Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME |
| CN110172455B (zh) * | 2019-05-31 | 2020-03-17 | 江南大学 | 一种脂肪酶突变体及其在去污方面的应用 |
| AU2020364959A1 (en) | 2019-10-07 | 2022-04-07 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for Nectin-4 and uses thereof |
| KR102280672B1 (ko) * | 2019-12-20 | 2021-07-23 | 주식회사 베르티스 | 암의 진단용 조성물 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| US20230235054A1 (en) * | 2020-06-18 | 2023-07-27 | Bioatla, Inc. | Conditionally active anti-nectin-4 antibodies |
| EP4168039A4 (en) * | 2020-06-19 | 2024-12-04 | Agensys, Inc. | MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) |
| US20230331867A1 (en) * | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| BR112022026611A2 (pt) * | 2020-09-16 | 2023-04-11 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticorpo ou fragmento de ligação ao antígeno do mesmo, conjugado de anticorpo, composição, receptor de antígeno quimérico, célula efetora imune, molécula de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para detectar a presença ou determinar o nível de expressão de nectina-4 em uma amostra |
| IL302818A (en) * | 2020-11-25 | 2023-07-01 | Innate Pharma | Treatment of cancer |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| BR112023022098A2 (pt) * | 2021-04-26 | 2023-12-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos |
| US12258402B2 (en) | 2022-01-12 | 2025-03-25 | Navi Bio-Therapeutics, Inc. | Antibody specific to nectin cell adhesion molecule 4 and uses thereof |
| EP4496593A1 (en) | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198008A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Compositions and methods for treating cancer |
| EP4310101A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibodies and antibody-drug conjugates |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| KR102584898B1 (ko) * | 2022-10-24 | 2023-10-04 | 연세대학교 산학협력단 | 자궁내막암 진단 방법 및 이를 이용한 키트 |
| WO2024251260A1 (zh) * | 2023-06-08 | 2024-12-12 | 江苏迈威康新药研发有限公司 | 结合Nectin-4的抗体及其用途 |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1747236A1 (en) | 2004-05-12 | 2007-01-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4(n4) as a marker for cancer prognosis |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| JP2012511305A (ja) | 2008-12-12 | 2012-05-24 | オンコセラピー・サイエンス株式会社 | 癌の治療および診断の標的遺伝子としてのネクチン−４ |
| EA201790850A1 (ru) | 2010-09-29 | 2017-11-30 | Эдженсис, Инк. | Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12 |
| WO2016203053A2 (en) | 2015-06-18 | 2016-12-22 | Thomas Mole Herd | Methods of characterising cancer |
| US10675357B2 (en) * | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
-
2018
- 2018-06-04 BR BR112019025513-3A patent/BR112019025513A2/pt unknown
- 2018-06-04 CA CA3065514A patent/CA3065514A1/en active Pending
- 2018-06-04 MX MX2019014318A patent/MX2019014318A/es unknown
- 2018-06-04 JP JP2019566609A patent/JP7168590B2/ja active Active
- 2018-06-04 US US16/619,439 patent/US11292837B2/en active Active
- 2018-06-04 KR KR1020197038453A patent/KR102723905B1/ko active Active
- 2018-06-04 WO PCT/US2018/035840 patent/WO2018226578A1/en not_active Ceased
- 2018-06-04 TW TW107119234A patent/TWI870338B/zh active
- 2018-06-04 CN CN202010492265.3A patent/CN111675761B/zh active Active
- 2018-06-04 EP EP18813335.9A patent/EP3635013A4/en active Pending
- 2018-06-04 CN CN201880049820.6A patent/CN111051345A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201902922A (zh) | 2019-01-16 |
| CA3065514A1 (en) | 2018-12-13 |
| EP3635013A4 (en) | 2021-02-24 |
| CN111675761B (zh) | 2023-10-20 |
| US11292837B2 (en) | 2022-04-05 |
| CN111675761A (zh) | 2020-09-18 |
| RU2019144030A3 (OSRAM) | 2021-12-28 |
| WO2018226578A8 (en) | 2019-05-31 |
| WO2018226578A1 (en) | 2018-12-13 |
| TWI870338B (zh) | 2025-01-21 |
| BR112019025513A2 (pt) | 2020-06-23 |
| RU2019144030A (ru) | 2021-07-09 |
| JP2020522261A (ja) | 2020-07-30 |
| US20200231670A1 (en) | 2020-07-23 |
| KR20200024788A (ko) | 2020-03-09 |
| CN111051345A (zh) | 2020-04-21 |
| JP7168590B2 (ja) | 2022-11-09 |
| KR102723905B1 (ko) | 2024-10-31 |
| EP3635013A1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014318A (es) | Proteinas de union a nectina-4 y metodos de uso de las mismas. | |
| PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| MX2021006786A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| EA201992757A1 (ru) | Биспецифические антитела-ингибиторы контрольной точки | |
| GEAP202215554A (en) | Pd-1-binding molecules and methods of use thereof | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
| MX2018001387A (es) | Anticuerpo de dominio simple y proteinas derivadas del mismo contra ligando de muerte programada (pdl1). | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof |